CD44 and prostate carcinoma: In breast and prostate cancers, previous studies have identified CD44+ or CD117+/ABCG2+ cells with stem-like characteristics, such as increased clonogenic/tumorigenic properties, higher expressions of stemness genes, and stronger ability to form tumors in animal models [19], [22], [23].